Does Wegovy 0.25mg do anything — or is it just a waiting game?

You've injected your first 0.25mg pen. Here's what to expect

Picture this: it's your first Monday on Wegovy. You've done the injection, put the pen away, and now you're waiting to feel something. Maybe you've read about 15% average weight loss in the STEP 1 trial published in the New England Journal of Medicine. The gap between that headline and what you feel this week can be disorienting.

The honest answer is that 0.25mg semaglutide does very little to your weight directly, a question many people have when they start out. The dose is too low to produce the sustained appetite suppression that drives meaningful fat loss. What it is doing is introducing GLP-1 receptor activity to your system gradually, which matters more than most people realise. Starting low dramatically reduces the nausea, diarrhoea and cramping that would otherwise hit hard if you jumped straight to a therapeutic dose. That's the entire rationale: comfort first, results later.

Some people do notice a subtle dulling of appetite or feel full a little sooner at meals. That's real, even a low level of GLP-1 receptor agonism affects gastric emptying and satiety signalling to the brain. But don't read too much into it. Whether those signals are pronounced or barely noticeable at 0.25mg varies considerably from person to person, and neither outcome tells you much about how you'll respond at higher doses.

One checking habit worth building now: weigh yourself on the same day each week, at the same time, before eating. Consistency matters more than frequency. A single number means little; a four-week trend tells a proper story.

Why the dose schedule is built the way it is

The titration pathway for Wegovy's dosing steps is fixed in the licensed schedule for a reason. After roughly four weeks at 0.25mg, the prescriber reviews your progress and tolerance before moving to 0.5mg, then 1.0mg, then 1.7mg, and finally the 2.4mg maintenance dose. Each rung takes approximately four weeks. That means the earliest most people reach maintenance is around week seventeen or eighteen.

Does 0.25mg semaglutide do anything beyond gut adjustment? It does build a physiological baseline. Your GLP-1 receptors are beginning to respond; your liver, pancreas and brain are all processing a new hormonal signal. Think of it less as a placebo and more as the calibration phase before the main programme begins. The NHS patient guide to semaglutide explains this step structure clearly and is worth reading alongside your Patient Information Leaflet.

People who try to rush this phase (pressing for a faster increase, or sourcing higher doses independently) tend to hit worse side effects with no better outcomes. The four-week spacing exists because it works. Your prescriber owns that timeline, not you, and not any pharmacy.

Side effects you might feel even at the lowest dose

Even at 0.25mg, the most commonly reported effects are gastrointestinal. Mild nausea is the one patients mention most, often in the hours after injection. Loose stools, burping, a feeling of early fullness that borders on uncomfortable, these are all possible, though generally milder at the starting dose than at higher ones. Fatigue and a light headache occasionally appear in the first week or two.

These effects tend to settle as your body adapts, usually within a few days to a couple of weeks. If anything is severe or persistent, contact your prescriber rather than waiting it out. For a broader picture of what's reported across the full dose range, the detail on the 0.25mg injection covers the evidence in more depth.

Serious reactions are rare but worth knowing. Severe or persistent abdominal pain, particularly if it spreads towards your back, needs prompt medical assessment. So does any sign of a significant allergic reaction. If you want to understand exactly how 0.25ml of Wegovy is measured and administered correctly, that guidance is worth reviewing before your next injection. The MHRA's Yellow Card scheme at yellowcard.mhra.gov.uk lets you report any suspected side effect, which contributes to ongoing post-market safety monitoring for all medicines including Wegovy.

When weight loss actually starts, and what to do if it doesn't

For most people, meaningful weight loss begins to show somewhere between weeks eight and sixteen, typically once the dose has climbed past 1.0mg. At 2.4mg maintenance, the STEP 1 trial found an average reduction of around 15% of body weight over 68 weeks, a significant result, but one that builds slowly from a foundation of careful titration.

If you have questions about what happens when it's time to step up from 0.25mg, the guide to moving from 0.25mg to 0.5mg walks through what to expect at that transition. And if you're still weighing up whether Wegovy is the right treatment for your situation, our weight-loss treatment overview compares the options available through a regulated UK pharmacy. Decisions about dose timing, tolerability and whether to continue are clinical judgements. If you'd like to talk through your options with a GPhC-registered prescriber, you can speak to our prescribers through a free consultation.